Home › All Companies › BIAFW › Annual Report

bioAffinity Technologies, Inc. (BIAFW) — Annual Report

AI-Powered SEC Filing Analysis

← All BIAFW filings
Latest Annual Report Filed: 2026-03-16

Key Insights

  • The company has reported a significant increase in revenue from its CyPath Lung diagnostic service, suggesting growing market adoption.
  • Expenses related to research and development as well as clinical trials have increased, indicating the company's focus on advancing its diagnostic pipeline.
  • The company has secured additional financing through a second finance agreement, which could provide the necessary capital to support its ongoing operations and growth initiatives.
Sentiment: Positive Significance: 6/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-03-16. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for bioAffinity Technologies, Inc.

Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.